Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
April 28, 2020 5:46 PM EDT
Today's After-Hours Stock Movers
RR Donnelley (NYSE: RRD) 40% HIGHER; reported Q1 EPS of $0.33, $0.37 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.41 billion versus the consensus estimate of $1.38 billion.
Chimerix (NASDAQ: CMRX) 22.5% HIGHER; announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.... More
April 28, 2020 5:06 PM EDT
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.... More
